AVANT BIO Recruits Biopharma Titans to Steer Portfolio Growth

NEW YORK, NY – May 26, 2026 – Growth equity firm AVANT BIO today announced a significant enhancement of its operational capabilities, appointing two of the biopharmaceutical industry's most seasoned executives, Maik W. Jornitz and Lukas Utiger, as Operating Advisors. The move signals a deliberate strategy to embed deep industrial expertise directly into its portfolio, aiming to accelerate the growth of companies developing the next generation of life science technologies.

In their new roles, Jornitz and Utiger will work directly with AVANT BIO's portfolio companies, providing hands-on support for operational scaling, business development, and strategic growth. Their engagement is expected to include serving on company boards, offering a direct line of C-suite-level experience to emerging businesses navigating the complex path from scientific innovation to commercial success.

This strategic reinforcement comes as the life sciences sector faces a critical inflection point. While scientific discovery is accelerating, the ability to manufacture and scale these breakthroughs—from advanced cell therapies to AI-driven diagnostic tools—has become a primary bottleneck. By adding Jornitz and Utiger, AVANT BIO is making a clear statement that it intends to provide its companies with not just capital, but the operational playbook to win in a highly competitive market.

A 'Dream Team' of Bioprocessing and Manufacturing

The combined experience of the two new advisors represents nearly eight decades of leadership at the forefront of bioprocessing and contract manufacturing. Their careers have not only tracked but actively shaped the evolution of how modern therapeutics are made.

Maik W. Jornitz brings over 40 years of experience, making him a globally recognized authority in bioprocessing, sterile filtration, and single-use technologies. His 26-year tenure at Sartorius saw him rise to Senior Vice President for Global Product and Marketing Management in its bioprocess division. He later spent a decade as CEO and President of G-CON Manufacturing, where he was a key figure in pioneering the modular cleanroom infrastructure that is now critical for the flexible manufacturing of advanced therapies. A former Chair of the Parenteral Drug Association (PDA) Board of Directors, Jornitz has been named to The Medicine Maker Power List three times, underscoring his influence on the industry.

"I am truly delighted to join the highly professional and widely respected team at AVANT BIO," said Maik Jornitz. "Their commitment to growth, strategic investment, and forward-looking biopharma vision creates an inspiring environment focused on innovation, quality, and long-term impact. I look forward to contributing to and supporting this exciting journey ahead."

Lukas Utiger offers a complementary skill set forged over three decades in executive leadership across the global Contract Development and Manufacturing Organization (CDMO) landscape. His 20-year career at Lonza Group AG culminated in his role as Chief Operating Officer of Lonza Bioscience. He went on to serve as President and CEO of DSM Pharmaceutical Products and later held senior leadership roles at Patheon, guiding the company through its merger and subsequent acquisition by Thermo Fisher Scientific. At Thermo Fisher, he served as Group Vice President for Asian Strategy, demonstrating his expertise in global operations. Utiger currently leads a life science consultancy and serves on the boards of major service providers including Abzena and Aenova.

"It is a great pleasure to join the energetic AVANT BIO team," said Lukas Utiger. "After many years managing large businesses globally, I am excited to engage with innovative technology startups who are scaling commercially. Our goal is to nurture faster growth and efficiency based on our extensive experience and expertise."

More Than Money: Catalyzing Value in a Complex Market

The appointments are a direct reflection of AVANT BIO's core philosophy: "We Catalyze Value." This approach moves beyond the traditional growth equity model of capital-for-equity, emphasizing active operational engagement to de-risk investments and accelerate value creation. In a sector as technically demanding as life science industrials, this hands-on model is becoming a crucial differentiator.

"Maik and Lukas are two of the most respected figures in bioprocess and biomanufacturing globally," stated Daniella Kranjac, Founding General Partner of AVANT BIO. "Their depth of operational experience, their networks across the strategic acquirer universe, and their track records of building and scaling life science businesses make them ideal partners for our portfolio companies."

The market context validates this strategy. The global bioprocess technology market is on a steep growth trajectory, projected to exceed $80 billion in 2026. This expansion is driven by the rise of complex biologics, cell and gene therapies, and an industry-wide push for greater efficiency and speed. However, this growth presents immense operational challenges, from developing scalable manufacturing processes and securing supply chains to navigating a stringent global regulatory environment. Having advisors who have built and run the very infrastructure these startups need to access is an invaluable asset.

A Strategic Fit for an Ambitious Portfolio

Founded in 2023, AVANT BIO has quickly assembled a portfolio of companies operating at the cutting edge of therapeutic enablement. Its investments include firms like Nomic, with its high-throughput protein profiling platform; PL BioScience, which develops sustainable, non-animal-derived cell culture media; and PathPresenter, an image management platform for digital pathology.

For these companies, the guidance of Jornitz and Utiger is not theoretical but immediately applicable. A company like PL BioScience can leverage Jornitz's deep knowledge of bioprocess design and single-use systems to ensure its innovative media can be seamlessly integrated into customers' manufacturing workflows. Nomic, as it scales its nELISA platform, can benefit from Utiger's vast experience in global commercialization and managing complex CDMO relationships. His insights into M&A and strategic partnerships, honed through the Patheon-Thermo Fisher deal, provide a roadmap for long-term value creation and successful exits.

The decision to place the advisors on portfolio company boards ensures this expertise is woven into the strategic fabric of each business. This direct governance role facilitates a deeper level of mentorship and oversight than a typical consulting arrangement, aligning the advisors' success directly with that of the companies they guide.

By assembling this level of operational firepower, AVANT BIO is positioning itself not merely as a financial backer, but as a strategic industrial partner. The move underscores a broader trend in private equity, where 'smart money' is increasingly defined by the depth of operational expertise a firm can bring to bear. In the high-stakes world of life sciences, this combination of capital and operational muscle may prove to be the critical catalyst for turning the next wave of scientific breakthroughs into world-changing therapies.